MAPT and Alzheimer disease: Alzheimer’s Disease (AD): EVs loaded with siRNA targeting pathological proteins (e.g., BACE1 or tau) delivered via RVG-functionalized exosomes reduced amyloid burden, attenuated neuroinflammation, and improved cognitive performance in transgenic mouse models [81].